
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

December 3, 2019
Date of Report (Date of earliest event reported)

Sophiris Bio Inc.
(Exact name of registrant as specified in its charter)

British Columbia
(State or other jurisdiction
of incorporation)

001-36054
(Commission File Number)

98-1008712
(IRS Employer Identification No.)

1258 Prospect Street
La Jolla, CA
(Address of principal executive offices)

92037
(Zip Code)

Registrant's telephone number, including area code: (858) 777-1760

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Common Shares, no par value

Trading Symbol(s)
SPHS

Name of each exchange on which registered
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On June 4, 2019, Sophiris Bio Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") notifying the Company that the closing bid price of the Company's common shares had been below \$1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Marketplace Rule 5550(a)(2).

Nasdaq stated in its June 4th letter that, in accordance with Marketplace Rule 5810(c)(3)(A), the Company had been provided a grace period of 180 calendar days, or until December 2, 2019, to regain compliance with the minimum closing bid price requirement for continued listing.

On December 3, 2019, the Company received a letter from the Nasdaq which noted that the Company had not regained compliance with the closing bid price requirement as of December 2, 2019. At this point in time, the Company does not qualify for a second 180-day period to regain compliance with the \$1.00 closing bid price requirement and therefore this deficiency serves as an additional basis for delisting of the Company's securities.

The Company has until December 10, 2019 to presents its views with respect to this additional deficiency to the Nasdaq Hearings Plan. The notification from Nasdaq does not have an immediate effect on the listing of the Company's common shares and the Company's common shares will continue to trade on The Nasdaq Capital Market under the symbol "SPHS".

The Company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements including but not limited to a potential reverse stock.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sophiris Bio Inc.

Dated: December 9, 2019

By: /s/ Peter Slover
Peter Slover
Chief Financial Officer